NCT06066437 - NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Prostate Cancer

Interventions

DRUG

Arm A: 177Lu rhPSMA-10.1

Participants will receive 177Lu rhPSMA-10.1 alone.

DRUG

Arm B: 177Lu rhPSMA-10.1 plus Degarelix

Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston